October 20, 2018

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

Key Points

Key points are not available for this paper at this time.

Abstract

Neoadjuvant pembrolizumab resulted in 42% of patients with pT0 and was safely administered in patients with MIBC. This study indicates that pembrolizumab could be a worthwhile neoadjuvant therapy for the treatment of MIBC when limited to patients with PD-L1-positive or high-TMB tumors.

Demander à l'IA

Bookmark

Cite This Study

Necchi et al. (Sat,) studied this question.

synapsesocial.com/papers/69dadbdb78a3e0e2886848da https://doi.org/https://doi.org/10.1200/jco.18.01148

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neoadjuvant PD-1 Blockade in Resectable Lung Cancer2018 · 2,137 citations
2Multiple-Stage Procedures for Drug Screening1973 · 89 citations
3Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer2016 · 350 citations
4A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).2018 · 90 citations
5Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Is Low Among Major European Centres: Results of a Feasibility Questionnaire2012 · 81 citations

Demander à l'IA

Bookmark